Table 3.
Study characteristics and study methodology.
Hip stems | Hip cups | Knees | All | |
---|---|---|---|---|
Number of articles | 63 | 34 | 54 | 151 |
Publication period | 1995–2021 | 2007–2021 | 2002–2021 | 1995–2021 |
Location (%) | ||||
Europe | 66.7 | 70.6 | 61.1 | 63.6 |
Americas | 23.8 | 0 | 29.6 | 19.9 |
Asia | 1.6 | 23.5 | 9.3 | 9.3 |
Other | 7.9 | 11.8 | 1.9 | 5.3 |
Study type | ||||
Case report | 3.2% | 11.8% | 1.9% | 4.6% |
Case–control | – | – | 5.6% | 2% |
Cohort registry based | 7.9% | 11.8% | 18.5% | 12.6% |
Other cohorts | 84.1% | 67.6% | 59.3% | 71.5% |
Retrospective* | 83.0% | 56.5% | 62.5% | 72.2% |
RCT | 4.8% | 8.8% | 14.8% | 9.3% |
Comparator group(s), yes | 41.3% | 23.5% | 59.3% | 43.7% |
Adjusted† analysis, yes | 25.4% | 5.9% | 38.9% | 25.8% |
Number of prostheses included | ||||
Mean | 615 | 613 | 1460 | 917 |
Median (range) | 139 (1–14’147) | 95 (1–14’147) | 180 (1–27’193) | 139 (1–27’193) |
Median inclusion period (years) | 3 | 2 | 3 | 3 |
Follow-up‡ (years) | 5.5 (0.1–17.8) | 5.0 (0.3–15.0) | 3.4 (1–13.4) | 4.6 (0.1–17.8) |
First inclusion date to publication in years‡ | 10 (4–22) | 9 (2–21) | 11 (3–20) | 10 (2–22) |
FDA approval to first publication in years‡ | 5 ((–8)–10) | 2 (1–3) | 5 ((–3)–8) | 5 ((–8)–10) |
CE-mark date to first publication in years‡ | 9 (3–13) | 10 (7–12) | 7 (5–10) | 9 (3–13) |
*Percentage of other cohorts; †matching instead of adjustment was used in 1 study; ‡values are median (range).